Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Depreciation and Depletion (2017 - 2025)

Historic Depreciation and Depletion for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $100000.0.

  • Aclaris Therapeutics' Depreciation and Depletion fell 5000.0% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $400000.0, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $700000.0 for FY2024, which is 1250.0% down from last year.
  • According to the latest figures from Q3 2025, Aclaris Therapeutics' Depreciation and Depletion is $100000.0, which was down 5000.0% from $100000.0 recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Depreciation and Depletion high stood at $200000.0 for Q1 2021, and its period low was $100000.0 during Q4 2022.
  • Moreover, its 5-year median value for Depreciation and Depletion was $200000.0 (2021), whereas its average is $173684.2.
  • As far as peak fluctuations go, Aclaris Therapeutics' Depreciation and Depletion plummeted by 5000.0% in 2022, and later surged by 10000.0% in 2023.
  • Aclaris Therapeutics' Depreciation and Depletion (Quarter) stood at $200000.0 in 2021, then tumbled by 50.0% to $100000.0 in 2022, then surged by 100.0% to $200000.0 in 2023, then tumbled by 50.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Its Depreciation and Depletion stands at $100000.0 for Q3 2025, versus $100000.0 for Q2 2025 and $100000.0 for Q1 2025.